Blood test may accelerate lymphoma diagnosis in low‑resource settings

Lymphoma, a group of blood cancers that arise in the immune system, affects nearly 80,000 Americans each year, with about 20,000 deaths reported in 2023. Because the disease can progress rapidly, clinicians emphasize that an accurate diagnosis is often a race against time. Early identification—distinguishing between indolent and aggressive subtypes—guides treatment decisions and can markedly improve survival rates, underscoring the need for prompt, precise evaluation.

Diagnostic work‑up typically begins with a physical exam and imaging studies such as PET/CT, followed by a biopsy of suspicious lymph nodes or bone marrow. Flow cytometry, immunohistochemistry, and next‑generation sequencing now complement traditional histology, allowing pathologists to classify lymphoma subtypes and detect actionable mutations. Despite these advances, delays still occur due to limited access to specialized centers, variable symptom presentation, and the need for multidisciplinary review. Ongoing efforts to streamline referral pathways, expand tele‑pathology services, and integrate artificial‑intelligence algorithms aim to reduce turnaround times and ensure that patients receive the most effective therapy as early as possible.